Galvin Roy 4

4 · HAEMONETICS CORP · Filed May 19, 2026

AI-generated summary of this filing

Updated May 19, 2026

Haemonetics (HAE) EVP Galvin Roy Receives 27,535 RSU Award; 879 Shares Withheld

What Happened

Galvin Roy, EVP and Chief Commercial Officer of Haemonetics Corporation (HAE), was granted 27,535 restricted stock units (RSUs) on May 15, 2026 (reported on Form 4 filed May 19, 2026). In connection with the vesting of previously reported RSUs, 879 shares were withheld to cover tax obligations at a price of $56.29 per share, totaling $49,479.
The 27,535 securities are RSUs (contingent rights to one share each) rather than open-market purchases or immediate sales.

Key Details

Transaction date: May 15, 2026; Form 4 filed: May 19, 2026 (timely filing).
Withheld shares: 879 shares at $56.29/share = $49,479 (tax withholding; transaction code F).
Award/grant: 27,535 RSUs (transaction code A); no per-share price reported for the grant.
Shares owned after transaction: Not specified in the Form 4 provided.
Notable footnotes: the reported amounts include unvested RSUs previously reported and 415 shares acquired under the Haemonetics Employee Stock Purchase Plan on April 30, 2026. RSUs vest 40% on the first anniversary, 40% on the second, and 20% on the third; each RSU converts to one share when vested.

Context

RSU grants are compensation awards that vest over time; they are not immediate cash purchases and generally indicate long-term compensation rather than an immediate bullish market bet. The 879-share transfer was a routine tax-withholding event tied to RSU vesting (code F), not an open-market sale.

Form 4

Period: 2026-05-15

EVP, Chief Commercial Officer

Transactions

Footnotes (4)

[F1]Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.
[F2]This number includes unvested RSUs previously reported as well as 415 shares acquired by the reporting person under the Haemonetics Corporation 2007 Employee Stock Purchase Plan (as amended and/or restated from time to time) on April 30, 2026.
[F3]The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the date of grant, forty percent vesting on the second anniversary of the date of grant and the remaining twenty percent vesting on the third anniversary of the date of grant.
[F4]Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

Signature

/s/ Thomas V. Powers, attorney-in-fact for Mr. Galvin|2026-05-19

1 file